Literature DB >> 17427185

Nuclear receptor NR4A2 IVS6 +18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese Parkinson's disease.

Chiung-Mei Chen1, I-Cheng Chen, Kuo-Hsuan Chang, Yi-Chun Chen, Rong-Kuo Lyu, Yen-Tzu Liu, Fen-Ju Hu, Chih-Ying Chao, Guey-Jen Lee-Chen, Yih-Ru Wu.   

Abstract

Both of environmental and genetic factors confer vulnerability to Parkinson's disease (PD). NR4A2 (Nurr1), a member of the steroid/thyroid hormone nuclear receptor superfamily, is essential for the neurogenesis and differentiation of dopaminergic neurons in the midbrain. Brain derived neurotrophic factor (BDNF) deficiency may play a role in the pathogenesis of PD, as the surviving dopaminergic nigrostriatal neurons have reduced levels of BDNF. This study examines whether BDNF V66M (c.196 G --> A) or NR4A2 IVS6 +18insG polymorphism is associated with the risk of Taiwanese PD and the age of onset using a case-control study. The genotype or allele frequency distribution of both BDNF V66M and NR4A2 IVS6 +18insG polymorphisms was not significantly different between the cases and the controls. Neither BDNF nor NR4A2 polymorphism influences PD onset age. Notably, after stratification by sex, female individuals carrying the NR4A2 2G/2G genotype demonstrated a trend toward significant decrease in risk of developing PD (OR = 0.49, 95% CI = 0.25-0.96, P = 0.039). These results suggest that the NR4A2 IVS6 +18insG polymorphism may play a minor role in PD susceptibility among Taiwanese women. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17427185     DOI: 10.1002/ajmg.b.30476

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  8 in total

Review 1.  NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.

Authors:  Mickael Decressac; Nikolaos Volakakis; Anders Björklund; Thomas Perlmann
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

Review 2.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

3.  Mitochondrial DNA polymorphisms and the risk of Parkinson's disease in Taiwan.

Authors:  C M Chen; C C Kuan; G-J Lee-Chen; Y R Wu
Journal:  J Neural Transm (Vienna)       Date:  2007-03-15       Impact factor: 3.575

4.  Nur-related receptor 1 gene polymorphisms and alcohol dependence in Mexican Americans.

Authors:  Ya-Ming Wei; Yan-Lei Du; Yu-Qiang Nie; Yu-Yuan Li; Yu-Jui Wan
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

Review 5.  Brain-derived neurotrophic factor in neurodegenerative diseases.

Authors:  Chiara Zuccato; Elena Cattaneo
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

6.  Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization.

Authors:  Maykel Cruz-Monteagudo; Fernanda Borges; Cesar Paz-Y-Miño; M Natália D S Cordeiro; Irene Rebelo; Yunierkis Perez-Castillo; Aliuska Morales Helguera; Aminael Sánchez-Rodríguez; Eduardo Tejera
Journal:  BMC Med Genomics       Date:  2016-03-09       Impact factor: 3.063

7.  Two novel heterozygous truncating variants in NR4A2 identified in patients with neurodevelopmental disorder and brief literature review.

Authors:  Xiaozhen Song; Wuhen Xu; Man Xiao; Yanfen Lu; Xiaoping Lan; Xiaojun Tang; Nanjie Xu; Guangjun Yu; Hong Zhang; Shengnan Wu
Journal:  Front Neurosci       Date:  2022-08-03       Impact factor: 5.152

Review 8.  BDNF Polymorphism: A Review of Its Diagnostic and Clinical Relevance in Neurodegenerative Disorders.

Authors:  Ting Shen; Yuyi You; Chitra Joseph; Mehdi Mirzaei; Alexander Klistorner; Stuart L Graham; Vivek Gupta
Journal:  Aging Dis       Date:  2018-06-01       Impact factor: 6.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.